Clal Biotechnology Industries Ltd. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was ILS 19.568 million compared to ILS 55.972 million a year ago. Net loss was ILS 35.286 million compared to net income of ILS 14.000 million a year ago. Basic loss per share from continuing operations was ILS 0.22 compared to basic earnings per share from continuing operations of ILS 0.09 a year ago. For the half year, total revenue was ILS 63.715 million compared to ILS 93.516 million a year ago. Net loss was ILS 37.912 million compared to net income of ILS 11.213 million a year ago. Basic loss per share from continuing operations was ILS 0.24 compared to basic earnings per share from continuing operations of ILS 0.07 a year ago.